Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | AGXT | P21549 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12933285 | 0.89 | CHRM2 (0.59) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL10442188 | 0.86 | TAAR1 (0.64) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL12384164 | 0.84 | TAAR1 (0.57) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL30080050 | 0.84 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL723511 | 0.84 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL17660560 | 0.84 | PPARG (0.44) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL30500298 | 0.83 | TAAR1 (0.44) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL13873033 | 0.82 | CHRM2 (0.52) | TAAR1CHRM2CHRM1CHRM3 | |
| SCHEMBL17523545 | 0.82 | CYP4F2 (0.42) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL2600046 | 0.82 | KDM4E (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760715-B2 | Modulators of lipoxygenase and cyclooxygenase enzyme activity | UNIVERSITÉ DE MONCTON (CA) | 2023-09-19 | — | — | US | disclosed |
| US-11760715-B2 | Modulators of lipoxygenase and cyclooxygenase enzyme activity | UNIVERSITÉ DE MONCTON (CA) | 2023-09-19 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-7709647-B2 | Tetrahydroquinoline cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709647-B2 | Tetrahydroquinoline cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| US-7569725-B2 | 2-[(3-chloro-4-hydroxybenzoyl)amino]-N-[2-(2-methoxyphenyl)ethyl]-5-phenoxybenzamide; therapeutic use as anti-cancer agents, as well as other therapeutic agents, for example, as anti-fertility agents | BRITSOL-MYERS SQUIBB COMPANY (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090105271-A1 | PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-23 | — | — | US | disclosed |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080113990-A1 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | TAAR1 77/4885CHRM2 30/4885CHRM1 32/4885 |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | TAAR1 4371/4885CHRM2 4092/4885CHRM1 4106/4885 |
| US-11760715-B2 | Modulators of lipoxygenase and cyclooxygenase enzyme activity | ALOX12, ALOX15B, ALOX5 | TAAR1 1230/4885CHRM2 1478/4885CHRM1 1904/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | TAAR1 3303/4885CHRM2 4658/4885CHRM1 4321/4885 |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | TAAR1 2280/4885CHRM2 529/4885CHRM1 876/4885 |
| US-20090105271-A1 | PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | TAAR1 2354/4885CHRM2 1242/4885CHRM1 2285/4885 |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | TAAR1 3699/4885CHRM2 4708/4885CHRM1 4749/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | TAAR1 3699/4885CHRM2 4708/4885CHRM1 4749/4885 |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | TAAR1 4425/4885CHRM2 4854/4885CHRM1 4863/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | TAAR1 4425/4885CHRM2 4854/4885CHRM1 4863/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | TAAR1 4425/4885CHRM2 4854/4885CHRM1 4863/4885 |
| US-20080113990-A1 | Biphenyl derivatives as modulators of voltage gated ion channels | TRPV1, TRPA1, TRPV2 | TAAR1 2896/4885CHRM2 647/4885CHRM1 1026/4885 |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | TAAR1 188/4885CHRM2 97/4885CHRM1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.